DE2111042A1 - Pharmazeutika mit entzuendungshemmender und analgetischer Wirkung - Google Patents
Pharmazeutika mit entzuendungshemmender und analgetischer WirkungInfo
- Publication number
- DE2111042A1 DE2111042A1 DE19712111042 DE2111042A DE2111042A1 DE 2111042 A1 DE2111042 A1 DE 2111042A1 DE 19712111042 DE19712111042 DE 19712111042 DE 2111042 A DE2111042 A DE 2111042A DE 2111042 A1 DE2111042 A1 DE 2111042A1
- Authority
- DE
- Germany
- Prior art keywords
- inflammatory
- hours
- formula
- pharmaceuticals
- analgesic effects
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000003110 anti-inflammatory effect Effects 0.000 title claims description 10
- 230000001760 anti-analgesic effect Effects 0.000 title description 3
- 239000003814 drug Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims description 8
- CBMVAKUXKULJRM-UHFFFAOYSA-N 2-(2-fluorophenyl)-1h-imidazole Chemical compound FC1=CC=CC=C1C1=NC=CN1 CBMVAKUXKULJRM-UHFFFAOYSA-N 0.000 claims description 6
- 230000001754 anti-pyretic effect Effects 0.000 claims description 5
- 230000000202 analgesic effect Effects 0.000 claims description 4
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 3
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 239000000047 product Substances 0.000 description 13
- 230000000694 effects Effects 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 229960002895 phenylbutazone Drugs 0.000 description 6
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- LEQAOMBKQFMDFZ-UHFFFAOYSA-N glyoxal Chemical compound O=CC=O LEQAOMBKQFMDFZ-UHFFFAOYSA-N 0.000 description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 239000001293 FEMA 3089 Substances 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 230000036592 analgesia Effects 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 229940015043 glyoxal Drugs 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- DHKHKXVYLBGOIT-UHFFFAOYSA-N 1,1-Diethoxyethane Chemical compound CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
- LYIIBVSRGJSHAV-UHFFFAOYSA-N 2-aminoacetaldehyde Chemical compound NCC=O LYIIBVSRGJSHAV-UHFFFAOYSA-N 0.000 description 1
- ZWDVQMVZZYIAHO-UHFFFAOYSA-N 2-fluorobenzaldehyde Chemical compound FC1=CC=CC=C1C=O ZWDVQMVZZYIAHO-UHFFFAOYSA-N 0.000 description 1
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR7008314A FR2081568B1 (enExample) | 1970-03-09 | 1970-03-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE2111042A1 true DE2111042A1 (de) | 1971-09-30 |
Family
ID=9051929
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19712111042 Pending DE2111042A1 (de) | 1970-03-09 | 1971-03-09 | Pharmazeutika mit entzuendungshemmender und analgetischer Wirkung |
Country Status (4)
| Country | Link |
|---|---|
| BE (1) | BE763907A (enExample) |
| DE (1) | DE2111042A1 (enExample) |
| FR (1) | FR2081568B1 (enExample) |
| GB (1) | GB1307810A (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010150200A (ja) * | 2008-12-25 | 2010-07-08 | Tosoh Corp | イミダゾール化合物およびその製造方法 |
-
1970
- 1970-03-09 FR FR7008314A patent/FR2081568B1/fr not_active Expired
-
1971
- 1971-03-08 BE BE763907A patent/BE763907A/xx unknown
- 1971-03-09 DE DE19712111042 patent/DE2111042A1/de active Pending
- 1971-04-19 GB GB2348171A patent/GB1307810A/en not_active Expired
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010150200A (ja) * | 2008-12-25 | 2010-07-08 | Tosoh Corp | イミダゾール化合物およびその製造方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| FR2081568A1 (enExample) | 1971-12-10 |
| GB1307810A (en) | 1973-02-21 |
| BE763907A (fr) | 1971-08-02 |
| FR2081568B1 (enExample) | 1973-04-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE1420072C3 (de) | (5'-Dibenzo- eckige Klammer auf a,e eckige Klammer zu -cycloheptatrienyliden)-piperidine, Verfahren zu ihrer Herstellung und Arzneimittel | |
| DE1645971C3 (de) | (lndazol-3-yl)-oxyessigsäurederivate, Verfahren zu ihrer Herstellung und Mittel mit entzündungshemmender Wirkung | |
| DE1618568B2 (de) | Benzyloxycarbonsaeuren und deren derivate, verfahren zur herstellung derselben und diese verbindungen enthaltende arzneimittel | |
| DD207718A5 (de) | Verfahren zur herstellung von 2-guanidino-4-heteroarylthiazolen | |
| DE2310031B2 (de) | 1 -Benzyl-1 H-indazol-3-carbonsäuren, -amide und -ester | |
| DE2616616A1 (de) | 1-(triarylalklyl)-4-phenylpiperidinderivate, verfahren zu ihrer herstellung und pharmazeutische zubereitungen, die diese verbindungen enthalten | |
| DE2514914A1 (de) | Verfahren zur herstellung tertiaerer amine | |
| DE1795402C3 (de) | 4-(3',4',5'-Trimethoxycmnamoyl)l-(äthoxycarbonylmethyl)-piperazin | |
| DE2053080A1 (de) | N substituierte Imidazole, Ver fahren zu ihrer Herstellung sowie ihre Verwendung als Arzneimittel | |
| DE2128375A1 (de) | Neue basische (Substituiert-alkyliden)amino-oxyalkylcarbonsäureester | |
| DE2111042A1 (de) | Pharmazeutika mit entzuendungshemmender und analgetischer Wirkung | |
| DE1967080C3 (de) | t-(3,4-Methylendioxybeiizoyl)-2methyl-5-methoxy-3-indolylessigsäureester, Verfahren zu ihrer Herstellung und Arzneipräparate | |
| DE2059949C3 (de) | Thienyl-fettsäurederivate, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Arzneimittel | |
| DD209628A5 (de) | Verfahren zur herstellung von imidazolinderivaten | |
| DE2160017C3 (de) | 3-(2-lsopropyl)-indolyl-pyridylketonderivate | |
| DE1545746A1 (de) | 2-[2-(5-Nitro-2-furyl)-yinyl]-pyridine und Verfahren zu deren Herstellung | |
| DE1955682C3 (de) | 2- [(MethylsulfinylVacetyl] -pyridin und Verfahren zu seiner Herstellung | |
| DE1618568C3 (de) | Benzyloxy car bonsäuren und deren Derivate, Verfahren zur Herstellung derselben und diese Verbindungen enthaltende Arzneimittel | |
| AT331216B (de) | Verfahren zur herstellung von neuen aminobenzylaminen sowie deren saureadditionssalzen | |
| AT221495B (de) | Verfahren zur Herstellung von neuen Dibenzocycloheptanderivaten und deren Salzen bzw. quaternären Ammoniumverbindungen | |
| DE2312256C3 (de) | 5-Pyrazol-essigsäurederivate, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Mittel | |
| AT331213B (de) | Verfahren zur herstellung von neuen aminobenzylaminen sowie deren saureadditionssalzen | |
| DE2404924A1 (de) | Ergolinderivate | |
| DE1620170C3 (de) | Neue Phenothiazinderivate und Verfahren zu ihrer Herstellung | |
| DE2049377A1 (de) | Arzneimittelzubereitungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OHA | Expiration of time for request for examination |